

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 October 2021 (28.10.2021)



(10) International Publication Number
WO 2021/216993 A1

(51) International Patent Classification:
A61K 48/00 (2006.01) *G01N 33/68* (2006.01)
G01N 33/50 (2006.01)

(21) International Application Number:
PCT/US2021/028829

(22) International Filing Date:
23 April 2021 (23.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/015,067 24 April 2020 (24.04.2020) US

(71) Applicant: PACT PHARMA, INC. [US/US]; 2 Corporate Drive, South San Francisco, CA 94080 (US).

(72) Inventors: JACOBY, Kyle; c/o Pact Pharma, Inc., 2 Corporate Drive, South San Francisco, CA 94080 (US). SEN-NINO, Barbara; c/o Pact Pharma, Inc., 2 Corporate Drive, South San Francisco, CA 94080 (US). FOY, Susan; c/o Pact Pharma, Inc., 2 Corporate Drive, South San Francisco, CA 94080 (US). HUNTER, Theresa, L.; c/o Pact Pharma, Inc., 2 Corporate Drive, South San Francisco, CA 94080 (US).

(74) Agent: LENDARIS, Steven, P. et al.; Baker Botts LLP, 30 Rockefeller Plaza, New York, NY 10012-4498 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS OF DETERMINING GENE EDITING EFFICIENCIES IN CELLS

Figure 1

Name	Sequence
Conserved	G D V E X N P G P
Sequence	(SEQ ID NO: 1)
T2A	E G R G S L L T C G D V E E N P G P (SEQ ID NO: 2)
P2A	A T N F S L L K Q A G D V E E N P G P (SEQ ID NO: 3)
E2A	Q C T N Y A L L K L A G D V E S N P G P (SEQ ID NO: 4)
F2A	V K Q T L N F D L L K L A G D V E S N P G P (SEQ ID NO: 5)

(57) Abstract: Methods of detecting the efficacy and presence of a biologic drug which uses one or more 2A peptide in its manufacture and/or final pharmaceutical formulation.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*